ArticleThe Journal of biological chemistry2026
Tissue-dependent enzymatic control of N-acetyl-β-alanine by PTER.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
β-alanine is one of the most abundant β-amino acids in mammals and occupies a central position at the intersection of vitamin, dipeptide, and energy metabolism. In addition to dietary intake, β-alanine availability in mammalian tissues is shaped by endogenous biochemical pathways, including pyrimidine catabolism, transamination reactions, and dipeptide turnover, and contributes to the synthesis of carnosine-related dipeptides that support cellular buffering and stress responses. Beyond these established biochemical fates, β-alanine also gives rise to secondary metabolites, including N-acetyl-β-alanine. Although N-acetyl-β-alanine has been associated with metabolic disorders such as obesity and type II diabetes, its enzymatic regulation and physiological relevance have remained unknown. Here we show that the N-acetyltaurine hydrolase phosphotriesterase-related (PTER) also catalyzes the hydrolysis of N-acetyl-β-alanine. In vitro, recombinant PTER converts N-acetyl-β-alanine to free β-alanine at a substantially faster rate than N-acetyltaurine hydrolysis, whereas structurally similar metabolites, including N-acetyl-α-alanine and N-acetyl-γ-aminobutyric acid (N-acetyl-GABA), are not substrates. Genetic ablation of Pter in mice results in a tissue-dependent reduction in N-acetyl-β-alanine hydrolase activity and leads to unexpected tissue-dependent bidirectional dysregulation of N-acetyl-β-alanine levels. Levels of carnosine and other β-alanine pathway metabolites remain unaffected. In contrast, N-acetyltaurine exhibits uniform accumulation across tissues in Pter-deficient mice. Circulating levels of N-acetyl-β-alanine and N-acetyltaurine are regulated in a substrate availability-dependent manner, and pharmacological elevation of N-acetyl-β-alanine suppresses feeding and obesity, although less effectively than N-acetyltaurine in a diet-induced obesity mouse model. Together, these findings demonstrate that PTER exerts tissue-dependent control of N-acetyl-β-alanine abundance, thereby defining a previously unrecognized regulatory node in β-amino acid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.